In Vivo CAR-T cell is one of the most promising and advanced cell therapies.
Following on from previous universal cell therapies such as autologous CAR-T, allogeneic CAR-T/CAR-NK,
in vivo CAR-T is one of those methods that can generate CAR-T/NK cells in vivo, thereby achieving the goal of lowering cell therapy costs and enhancing efficiency.
CAR-NK, also known as enhanced NK cells, is modified by genetic engineering to make NK cells express CAR molecules,
enhancing the selective killing effect of NK cells on tumor cells.
As a source of NK cells, iPSC (induced pluripotent stem cells) have gained a lot of attention because of their easy source,
strong differentiation, infinite expansion, low cost, high cell consistency, and significantly reduced preparation difficulty and cost.